期刊
MANAGERIAL AND DECISION ECONOMICS
卷 38, 期 4, 页码 581-594出版社
JOHN WILEY & SONS LTD
DOI: 10.1002/mde.2805
关键词
-
Pharmaceutical firms are reluctant to disclose proprietary information about a drug's likelihood of approval by the U.S. Food and Drug Administration (FDA) for fear of losing their competitive advantage. Instead, firms may use signals, like the FDA fast-track designation, to indicate to investors the likelihood of a drug's approval. This analysis uses an event study methodology, with stock and market data from the Center for Research in Security Prices. The results show that the fast-track designation is a strong, positive signal to investors (1998-2015), but its strength has markedly decreased over time. Results also show that the signal is strongest for the smallest firms. Copyright (C) 2016 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据